CD34+ bone marrow stem cells intravitreal for Retinitis Pigmentosa
Study Summary
This trial is to see if it's safe to inject stem cells from bone marrow into the eye to treat blindness from various retinal conditions.
- Retinitis Pigmentosa
- Age-Related Macular Degeneration
- Retinal Vein Occlusion
- Diabetic Retinopathy
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Does this study's eligibility criteria restrict those aged eighteen or older?
"This medical trial will include patients that are at least 18 years old and not older than 100."
Is there an opportunity for me to participate in this experiment?
"Eligibility criteria for this clinical trial necessitates that potential participants possess retinitis pigmentosa and be between 18 to 100 years of age. Approximately 15 candidates will be selected in total."
Are there any federal regulations for intravitreal injections of CD34+ bone marrow stem cells?
"Owing to the limited clinical data surrounding CD34+ bone marrow stem cells intravitreal, it was assigned a score of 1 on our safety scale. This assessment is reflective of its Phase 1 status."
Is this research study recruiting participants at this time?
"The data from clinicaltrials.gov shows that this particular trial, which was originally added on July 1st 2012 and last updated on August 8th 2022, is no longer accepting candidates. Fortunately, there are 299 other trials in need of participants currently available."